Rate My Professor Ernst Wolvetang

Professor Ernst J. Wolvetang is a Professor in stem cell biology at the Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, serving as Senior Group Leader of the Wolvetang Group, head of the Stem Cell Engineering Laboratory, director of the Australian Organoid Facility, and UQ-StemCARE Director. He earned his PhD in 1992 from the Department of Biochemistry at the University of Amsterdam for research on peroxisomal disease, followed by postdoctoral studies at Monash University's Department of Biochemistry and Institute for Reproduction and Development, focusing on apoptosis, Down syndrome, and Ets transcription factors. Joining the Australian Stem Cell Centre in 2003, he pioneered human embryonic stem cell research in Australia and led the Reprogramming and Induction of Pluripotency Collaborative Stream until 2011. Recruited to AIBN in 2008, he initiated and leads Cell Reprogramming Australia, coordinating iPSC research across Australia and the Asia-Pacific.

An international leader in pluripotent stem cell biology and human functional genomics, Professor Wolvetang specializes in reprogramming somatic cells to induced pluripotent stem cells (iPSCs), CRISPR-Cas9 genome editing for disease modeling, and generating brain and spinal cord organoids to investigate neurological diseases, ageing-related conditions such as Alzheimer's, and therapeutic development including small molecules, mRNA, and gene therapies. He has attracted over $2.5 million in grants over the past five years, including NHMRC MRFF projects on genetic epilepsies and hereditary spastic paraplegias, and ARC Discovery Projects. Awards include the 2016 Scopus Eureka Prize for Excellence in International Scientific Collaboration and the 2014 LSQ/AON Regenerative Medicine Prize. Select publications feature "Deconstructing heterogeneity of replicative senescence in human mesenchymal stem cells at single cell resolution" (GeroScience, 2023), "Inhibition of the cGAS-STING pathway ameliorates the premature senescence hallmarks of Ataxia-Telangiectasia brain organoids" (Ageing Cell, 2021), and "CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells" (Nature Biotechnology, 2006). He serves on editorial boards of six stem cell journals and is listed inventor on four stem cell patents.